Connect with us
  • ciitech


“I’m not a bad person” – chronically ill woman convicted of growing medical cannabis



Earlier this year Lisa Middleton was convicted of growing medical cannabis. She tells Cannabis Health why she won’t stop using the only medicine that helps manage her terminal conditions.

On Wednesday 25 April 2018 Lisa Middleton’s life changed when she woke up to a knock at the door at 9.15am.

She remembers seven police cars in the street outside and dozens of officers lining the kitchen, hallway and staircase while they searched the property where she was living in Sheffield.

Lisa, then 41, says she stayed surprisingly calm as they arrested her and took her into custody on the discovery of the 50 cannabis plants she was growing for personal, medical use.

“Looking back I should have been really scared, but because it happened as quickly as it did, I didn’t have time to think about it,” she says.

“I didn’t feel like I was a criminal.”

A few months earlier, the former hairdresser had lost her business of 10 years and had been made homeless. Living with a friend and with no income, she was forced to start growing the cannabis which she had relied on to keep her well for over 20 years.

Lisa suffers from a myriad of chronic health conditions, including severe cervical spondylosis, radial dysplasia and moderate heart failure.

She uses cannabis to manage her pain, help with circulation problems, combat nausea and boost her appetite, as well as easing her stress, anxiety and mental health issues.

“I’ve always smoked it rather than taking a supplement because it gives me more of an umbrella effect, treating everything rather than just targeting something specific,” she says.

“I knew I was breaking the law but I’d completely hit rock bottom. I felt like I had no other option.”

It was two years later when Lisa was finally charged with production of a Class B drug, under the Misuse of Drugs Act.

“It’s a hell of a long time to have it hanging over you, you’re living in limbo,” says Lisa, now 44.

“My health has deteriorated a lot in that time but I’ve got my own place now and my situation has completely changed.”

She continues: “I found it more traumatic when I got the court date, because I’ve never been in that situation in my life. You don’t know what to expect, and it’s a really scary experience.”

After her story appeared in the local press, Lisa felt some friends distanced themselves from her and instead she found support in the cannabis community, after deciding to speak openly to try and take back ownership of what had happened.

“It was worse after the arrest, I felt like a dead man walking. I thought, it’s out there I’ve got to own it and take back some control.”

She adds: “I noticed that friends distanced themselves, because of the criminality of it, even though they have known me for 15 or 20 years.

“Those in the cannabis community who I have been involved with personally, here in the UK and the US and Canada, have been the most supportive, non-judgemental people I’ve ever met.”

Some of those supporters were waiting outside Sheffield Crown Court on 15 July 2020 when Lisa was handed an 18 months suspended sentence, a 20 day rehabilitation requirement and 100 hours community service.

The Judge is reported to have acknowledged there had been a long delay before the case came to court and her previous good character.

But despite feeling incredibly relieved not to have been given a custodial sentence, she now has to face life with a permanent criminal record.

“Yes I got a suspended sentence, but I’m not free. There are certain stipulations that go along with that,” she says.

This includes weekly conversations with her probation officer to check that she is not going to reoffend, as well as partaking in a women’s rehabilitation group.

Lisa adds: “Two of my conditions are terminal, there’s no cure and ultimately they are going to take my life – going by the statistics I could be dead in two years.

“It makes you wonder, would they actually have sentenced a cancer patient?”

She now openly campaigns for a relaxation in the laws around cannabis, particularly for those like herself, who use it for medical purposes and can’t afford or don’t have access to a private prescription.

“I’m not saying I shouldn’t have been held accountable for breaking the law but I definitely believe that there needs to be a different structure in place for people like me,” she explains.

“They know that I wasn’t dealing, it was an isolated incident as a result of circumstances and I was taken through the court system in the same way as murders, rapists and violent offenders, for a victimless crime.”

She continues: “The black market is the only way we can access it, and now I’ve been criminalised for it I’m forced to go back and fund those illicit sources.”

“It’s a violation of fundamental rights for people not to be able to access the medication that works for them.

“It’s not going to be the cure for everyone, but the benefits far outweigh any negatives.”

While she would never take the risk of growing her own plants again, Lisa has no intention of stopping smoking cannabis.

She says: “Everybody knows that I’m still consuming cannabis, it’s my glue, it keeps me together.

“Technically I am a criminal because I’ve got a criminal record but we have to stop looking at people who are forced to access it illegally in that way,” she adds.

“I smoke cannabis, that doesn’t make me a bad person”













Case Studies

‘NHS asking children to come off meds for clinical trials could kill them’



Parents have warned that ‘washing out’ their children’s medication to enter into clinical trials could put their lives at risk.

The parents of children with severe, life-threatening epilepsy say that insisting that they come off their medication to take part in NHS trials is ‘unethical’.

It comes after the Department of Health appears to have reversed its position on observational trials, insisting that randomised control trials (RCTs) are held before medical cannabis is made more widely available on the NHS.

Following a review into the lack of access held by the Government department last year, the NHS proposed two RCTs and an observational study.

This would take into account the cases such as eight-year-old Murray Gray, who has been seizure-free for 17 months since taking medical cannabis.

A programme of two randomised controlled clinical trials is now being developed by the National Institute for Health Research, with ministers insisting this is the ‘best course of action’ to build evidence.

These trials would require participants to undergo a ‘washing out’ period beforehand, during which they would have to come off their current medication.

Joanne Griffiths, whose son Ben, 11, has treatment-resistant epilepsy has seen his condition improve significantly since he obtained a private prescription last year.

However, her local NHS trust and leading children’s hospital, Alder Hey Children’s NHS Foundation Trust, refuses to prescribe the medication until these trials have been carried out.

During a meeting last year lead neurologists and hospital bosses said they were ‘keen’ to be involved in upcoming trials.

However, Joanne was told that Ben and other children who have already had access to THC products, will be offered a ‘wash out’ period to be eligible for the study.

“Asking these children to wash out their current medicines could kill them, it’s putting their life at risk,” said Joanne.

When Ben was on epidiolex – a drug containing CBD which is prescribed for severe epilepsy – he was having up to 300 seizures a day and was ‘near death’.

“I wouldn’t swap my child from something that is working to something that possibly won’t,” she continued.

“It’s unethical what they are asking us to do.

“We’ve managed to reduce every single one of Ben’s antiepileptic drugs that were not working to control his hundreds of seizures. The only thing that is stopping him having seizures right now is cannabis, if we were to remove that from his system he could go back to having hundreds of seizures and could die.”

Elaine Levy’s daughter Fallon, 26, has been taking medical cannabis since 2018. She saw an instant deterioration in her condition when she tried a cheaper oil to help manage the costs.

“Taking these kids off their medicine they could end up being blue-lighted to hospital, they could die or they might just go back to smashing their head against the floor again,” said Elaine.

“They can’t do that to these children and young adults whose lives have been changed so dramatically thanks to medical cannabis.”

She added: “The whole thing is just astonishing, it’s just the hippocratic oath. You can’t take a person off of something that is working for them and then give them a placebo instead.”

More than 30 cross-party MPs have now signed a letter to Health Secretary Matt Hancock calling for him to release emergency funding to help families cover the costs of prescriptions until they become available on the NHS.

A spokesperson for Alder Hey Children’s NHS Foundation Trust said they could not comment on individual cases.

They said: “Alder Hey is at the forefront for children’s health research and is a founding partner of the NIHR Clinical Research Network for Children. The Trust will continue to engage in supporting any new, well designed and robust clinical trials that investigate the role of cannabis-based medicinal products in drug resistant paediatric epilepsy.

“All studies take into account safety considerations for all potential recruitment candidates and the safety of all patients remains paramount.”

Continue Reading


First Medical Cannabis Awareness Week launches in the UK – how you can get involved



The first Medical Cannabis Awareness Week is calling for access to NHS prescriptions two years on from the landmark law change.

Taking place from 1-8 November 2020 the inaugural Medical Cannabis Awareness Week (MCAW) will bring together patients, doctors, advocates and organisations to call for fair access to medical cannabis on the NHS.

On 1 November 2018, the law changed to allow UK patients access to medical cannabis. But since then, only a handful of prescriptions have been issued by the NHS.

Patients are struggling to fund private prescriptions – costing several hundreds of pounds a month – and up to 1.4 million people are forced to turn to the illegal cannabis market.

Most patients prescribed medical cannabis live with chronic pain, neurological or psychiatric conditions, such as fibromyalgia, multiple sclerosis, epilepsy, anxiety & PTSD – yet many continue to face stigma in their day-to-day lives and from healthcare professionals when trying to access this treatment.

Launched by PLEA (Patient-Led Engagement for Access) – a community of medical cannabis patients and advocates – throughout the week patients from across the UK will share their stories about the life-changing impact of medical cannabis and their difficulties in accessing a prescription.

Individuals and organisations from across the sector will take part in online events including a tour of a legal cannabis growing facility, and conversations with patients and doctors.

PLEA advocacy director Lucy Stafford took addictive opiate-based painkillers nearly every day of her teenage years to cope with the debilitating symptoms of the connective tissue disorder called Ehlers Danlos Syndrome.

“I had to drop out of school and live with the horrendous side effects. I was a shadow of myself,” she said.

“When I was prescribed medical cannabis, it changed everything. I’ve learnt to walk after years using a wheelchair and now attend university – I’ve got my life back. All patients in need should have the same chance to live a better quality of life – we need NHS access.”

The PLEA Community will host MCAW during the first week of November each year.

As part of the awareness week, people are encouraged to talk about medical cannabis with  their friends and family, record and share their own story, write to their MPs and even play medical cannabis bingo (have you been called a stoner when talking about your medicine? Has anyone ever suggested you’re just after a legal high?)

“It’s time to end the inequality and ensure everyone who needs it has the opportunity to benefit from medical cannabis treatment,” said Abby Hughes, PLEA outreach director.

“During MCAW, we’re calling for fair access, we’re promoting medical cannabis education for all and we’re directly addressing the stigma faced by patients. We want people to have conversations about cannabis, ask questions and be open-minded.

“Cannabis medicines are changing people’s lives around the world. In the UK, people are forced to pay privately, and it’s not right. Medical cannabis is keeping children with severe forms of epilepsy alive, and it’s allowing people with chronic illnesses and conditions to live normal lives.”

PLEA advocates for quality of life with medical cannabis, enabling patients to access their medicine free from stigma, geographical inconsistencies, and financial barriers and supports research into the safety and efficacy of cannabis-based medicinal products, to enable evidence-based prescription for all.

Dr Mala Mawkin, head of market development at Cellen Health and advisory board member at PLEA added: “Even though doctors have been able to prescribe Cannabis based Medicinal Products since 2018, healthcare professionals are still not equipped with the knowledge and tools to prescribe in the UK.

“We have made huge progress to be able to have pharmaceutical-grade THC/CBD medicines for patients that are cheaper and safer than the illicit market. The next steps are to invest in research, medical education and address the stigma faced by patients.

“Events during MCAW are here to show patients and healthcare professionals it is essential to talk openly about medical cannabis to address the unmet clinical needs of people living with chronic conditions.”

You can join advocates and organisations to share your PLEA on social media using the hashtag #MCAW2020

Follow @PLEA_community on Twitter and Instagram.

For more information and full programme visit

Continue Reading


How Europe’s first medical cannabis tracking app could revolutionise care



An innovative medical cannabis app has launched in the UK and it’s putting patients front and centre of their care.

Launching on Tuesday 27 October, Eva is a new platform to help patients consuming cannabinoid medications manage their symptoms and capture critical data on the safety and effectiveness of medical cannabis.

The app has been developed by digital therapeutics company Alta Flora and allows patients to record symptoms, medication consumption and quality of life through their phone.

It includes features for patients to add and track symptom severity and medication use –  with functionality for multiple symptoms and medicine routes of administration, such as dose and formulation.

It also allows users to explore trends through interactive tools and assess their quality of life using validated scales and questionnaires, with a clinically valid framework used by NICE (National Institute for Care and Excellence).

It has been designed for use by all patients, however they access their medication.

Alta Flora’s research found a range of challenges facing patients considering medical cannabis as a treatment, including a lack of data of medical cannabis products, stigmatisation within the healthcare system and a lack of access to prescribers and products.

Commenting on the launch, Gavin Sathianathan, CEO and founder of Alta Flora, said: “It has been two years since cannabis was made legal for medical purposes in the UK and since

then, access to these life-changing medicines for patients has barely improved.

“This failure largely rests on a lack of data, the absence of which deprives doctors and

clinicians of the confidence to prescribe it as a treatment.”

Gavin told Cannabis Health that patients who were tracking their symptoms and consumption were then able to have more open discussions about cannabis with their doctors.

“The nature of cannabis medicines means that the patient is required to listen to their own body –  it’s not a standardised thing that you can just get from a doctor, it requires patient-centric tools for us to understand and that’s what we are trying to build,” he said.

“Those patients who took that data to their clinicians found they were engaging with their doctors in a way that was educating them and they were able to have less stigmatised conversations.”

Eva also includes tools for researchers to organise studies within their organisation, such as clinics who want to capture data on their own patients.

“The future of healthcare is patient-centric care. The voice of the patient is becoming much more important, they have a seat at the table now,” he said.

According to Gavin the evidence base produced by Eva will serve both patient and industry needs and could play a key role in providing much-needed data for the safety and efficacy of products, ensuring wider acceptance of medical cannabis.

“We’ve got some really motivated patients who often, after trying lots of different medicines have found that cannabis does work and want to contribute data to improve access for patients in the UK,” he continued.

“We’ve got an opportunity to build a data set to help clinics, prescribers and regulators, understand the impact of cannabis on patients symptoms and quality of life in a lot more detail.”

Gavin also hopes the platform could also be used to track the effectiveness of CBD products on pain, anxiety and sleep,

But Eva’s potential expands beyond cannabis – particularly in a post-pandemic era, he says.

“When we shared what we were doing with academics and researchers it became clear that this idea of instrumenting in real-time the consumption of medicines is valid beyond cannabis,” Gavin added.

“In a post-COVID context, we’re thinking much more about preventative medicine and staying well.

“We’ve had enquiries from the psychedelic space and for monitoring medication used to treat conditions such as diabetes and ADHD.”

Academics from leading UK charity Drug Science have played a role in design, and content from a range of organisations including the Medical Cannabis Clinicians Society, Primary Care

Cannabis Network, MedCannID, PLEA, and CPASS is integrated into Eva.

The service is fully GDPR compliant and will include patient safety monitoring features

and real-time reporting dashboards for clinicians.

Eva is available to download on the Android store. The iOS version will be available from early December.

Continue Reading

Recent Articles